anastrozole and Hormone-Dependent Neoplasms studies

Research Excerpts

Excerpt	Relevance	Reference
"Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer."	9.22	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. ( Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C, 2016)
"27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily."	9.19	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014)
"Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial."	9.16	Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012)
" In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer."	9.16	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. ( Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A, 2012)
"We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment."	9.16	Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. ( Clarke Hillyer, G; Crew, KD; Danaceau, J; Hershman, DL; Kalinsky, K; Maurer, MA; Neugut, AI; Rotsides, DZ, 2012)
"To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer."	9.16	FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012)
"Given its favourable risk-benefit profile, the combination of anastrozole plus goserelin could represent an alternative neoadjuvant treatment option for premenopausal women with early-stage breast cancer."	9.16	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. ( Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y, 2012)
"In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy."	9.15	The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. ( Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H, 2011)
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)."	9.14	Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)
"The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0-2, M0), or potentially operable (T4b, N0-2, M0) breast cancer."	9.12	Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. ( Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y, 2006)
"In a double-blind, placebo-controlled randomised trial of 56 postmenopausal patients with ER-positive and EGFR-positive primary breast cancer, 27 women were randomly assigned to the tyrosine-kinase inhibitor of EGFR gefitinib (250 mg given orally once a day) and the aromatase inhibitor anastrozole (1 mg given orally once a day), and 29 women to gefitinib (250 mg given orally once a day) and placebo of identical appearance to anastrozole given orally once a day, all given for 4-6 weeks before surgery."	9.11	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. ( Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D, 2005)
"A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)."	9.10	Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003)
"Results from two studies, the North American trial and the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) trial carried out in Europe/rest of the world comparing 'Arimidex' (anastrozole) 1 mg with tamoxifen 20 mg for treatment of advanced breast cancer in postmenopausal women, have previously been reported individually and as a prospectively combined analysis."	9.10	Advanced breast cancer updates on anastrozole versus tamoxifen. ( Nabholtz, JM, 2003)
"Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer."	8.95	Fulvestrant for hormone-sensitive metastatic breast cancer. ( Goodwin, A; Lee, CI; Wilcken, N, 2017)
"Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer."	8.84	Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. ( Plosker, GL; Sanford, M, 2008)
"Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months."	7.80	Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014)
"To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer."	7.78	Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012)
"Weight gain is commonly reported by breast cancer patients on tamoxifen or aromatase inhibitors."	7.78	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. ( Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I, 2012)
"Study 1: Blood was collected from ten postmenopausal women with breast cancer before and after two-week treatment with anastrozole and serum concentrations of androstenediol and other androgens and estrogens were assessed."	7.77	Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. ( Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R, 2011)
"Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer."	7.74	Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008)
"Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro."	7.73	Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005)
"To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors."	7.73	Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006)
"A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years."	7.72	Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004)
"Treatment with tamoxifen may still be useful upon subsequent progression."	6.71	Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and ( Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B, 2004)
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen."	6.42	Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004)
"The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk."	5.35	IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008)
"Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer."	5.22	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. ( Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C, 2016)
"27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily."	5.19	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014)
"We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment."	5.16	Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. ( Clarke Hillyer, G; Crew, KD; Danaceau, J; Hershman, DL; Kalinsky, K; Maurer, MA; Neugut, AI; Rotsides, DZ, 2012)
" In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer."	5.16	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. ( Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A, 2012)
"Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial."	5.16	Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012)
"Given its favourable risk-benefit profile, the combination of anastrozole plus goserelin could represent an alternative neoadjuvant treatment option for premenopausal women with early-stage breast cancer."	5.16	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. ( Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y, 2012)
"To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer."	5.16	FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012)
"In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy."	5.15	The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. ( Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H, 2011)
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)."	5.14	Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)
"To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin."	5.14	Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. ( Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V, 2010)
"Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial."	5.12	A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007)
"The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0-2, M0), or potentially operable (T4b, N0-2, M0) breast cancer."	5.12	Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. ( Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y, 2006)
"In a double-blind, placebo-controlled randomised trial of 56 postmenopausal patients with ER-positive and EGFR-positive primary breast cancer, 27 women were randomly assigned to the tyrosine-kinase inhibitor of EGFR gefitinib (250 mg given orally once a day) and the aromatase inhibitor anastrozole (1 mg given orally once a day), and 29 women to gefitinib (250 mg given orally once a day) and placebo of identical appearance to anastrozole given orally once a day, all given for 4-6 weeks before surgery."	5.11	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. ( Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D, 2005)
"Results from two studies, the North American trial and the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) trial carried out in Europe/rest of the world comparing 'Arimidex' (anastrozole) 1 mg with tamoxifen 20 mg for treatment of advanced breast cancer in postmenopausal women, have previously been reported individually and as a prospectively combined analysis."	5.10	Advanced breast cancer updates on anastrozole versus tamoxifen. ( Nabholtz, JM, 2003)
"A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)."	5.10	Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003)
"Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer."	4.95	Fulvestrant for hormone-sensitive metastatic breast cancer. ( Goodwin, A; Lee, CI; Wilcken, N, 2017)
"We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients."	4.95	Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. ( He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017)
"A systematic review was undertaken to review the evidence for the use of third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) as adjuvant therapy for post-menopausal women with early-stage, hormone receptor-positive breast cancer and to develop and support recommendations for their use, with regard to three areas: aromatase inhibitors compared to tamoxifen, aromatase inhibitors in sequence with tamoxifen for a total of five years, and aromatase inhibitors given after five years of tamoxifen therapy."	4.84	Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. ( Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M, 2008)
"The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer."	4.84	Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007)
"Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer."	4.84	Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. ( Plosker, GL; Sanford, M, 2008)
"Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy."	4.82	A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003)
"The latest generation of nonsteroidal aromatase inhibitors (anastrozole and letrozole) has been approved by the US Food and Drug Administration for use in the first- and second-line treatment of postmenopausal women with hormone receptor-positive (or unknown) breast cancer."	4.82	Pharmacokinetics of third-generation aromatase inhibitors. ( Lønning, P; Martoni, A; Pfister, C; Zamagni, C, 2003)
"New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC)."	4.82	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E, 2005)
"With recent results showing letrozole and anastrozole to be superior to tamoxifen as initial therapy for advanced disease, the aromatase inhibitors are poised to establish their place in the adjuvant therapy of postmenopausal receptor-positive breast cancer."	4.81	Preliminary data from ongoing adjuvant aromatase inhibitor trials. ( Goss, PE, 2001)
"The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy."	4.81	A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001)
"Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer."	4.81	Nonsteroidal and steroidal aromatase inhibitors in breast cancer. ( Hamilton, A; Volm, M, 2001)
"Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months."	3.80	Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014)
"To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer."	3.78	Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012)
"Weight gain is commonly reported by breast cancer patients on tamoxifen or aromatase inhibitors."	3.78	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. ( Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I, 2012)
"Study 1: Blood was collected from ten postmenopausal women with breast cancer before and after two-week treatment with anastrozole and serum concentrations of androstenediol and other androgens and estrogens were assessed."	3.77	Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. ( Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R, 2011)
"A gene expression signature derived from ER(+) breast cancer cells with acquired hormone independence predicted tumor response to aromatase inhibitors and associated with clinical markers of resistance to tamoxifen."	3.77	A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. ( Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H, 2011)
"We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen."	3.77	Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011)
"The lower incidence of gynecologic adverse events and interventions with anastrozole and the early occurrence of these events provide further support for using anastrozole as the initial adjuvant treatment for early hormone receptor-positive breast cancer."	3.75	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. ( Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A, 2009)
"Taken together, data indicate that SERMs/antiestrogens and aromatase inhibitors exhibit opposed effects on the ER expression of breast cancer cells: tamoxifen and fulvestrant up-regulate ERalpha expression, while aromatase inhibitors increase ERbeta expression, which may contribute to the aromatase inhibitors' therapeutic superiority over antiestrogens."	3.75	Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. ( Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P, 2009)
"Post-menopausal breast cancer patients scheduled to receive tamoxifen (n=31) or anastrozole (n=14) completed neuropsychological testing around the time of commencement of treatment (T1), and again 5-6 months later (T2)."	3.75	Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. ( Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S, 2009)
"Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence."	3.74	Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008)
"Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer."	3.74	Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008)
"To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors."	3.73	Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006)
"We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil."	3.73	t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006)
"Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro."	3.73	Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005)
"The third-generation aromatase inhibitors (AIs) have improved efficacy and safety versus tamoxifen for treatment of advanced breast cancer."	3.72	Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. ( Buzdar, AU, 2004)
"A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years."	3.72	Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004)
"High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen."	3.71	Estrogen as therapy for breast cancer. ( Ingle, JN, 2002)
"To determine the effects of aromatase inhibitors on oestrogen uptake, in situ aromatase activity and endogenous oestrogens in the breast, postmenopausal women with large primary ER-rich breast cancers have been treated neoadjuvantly for 3 months with either letrozole (2."	3.71	Local endocrine effects of aromatase inhibitors within the breast. ( Dixon, JM; Miller, WR, 2001)
"Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2."	3.71	Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001)
"Women with early stage breast cancer exhibited an unexpectedly low TFCA, most likely due to their high calcium intake."	2.77	Aromatase inhibitors and calcium absorption in early stage breast cancer. ( Burkard, ME; Crone, E; Davis, LA; Gogineni, J; Hansen, KE; Shafer, MM; Tevaarwerk, A; Wisinski, KB, 2012)
"Treatment with tamoxifen may still be useful upon subsequent progression."	2.71	Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and ( Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B, 2004)
"Given the common hormonal dependence of breast cancer and the potential synergistic effect of these two treatment modalities, this strategy has been increasing in the adjuvant setting."	2.45	[Adjuvant breast cancer treatment with hormono-radiotherapy]. ( Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K, 2009)
"Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy."	2.44	Reducing the risk of late recurrence in hormone-responsive breast cancer. ( Cufer, T, 2007)
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen."	2.42	Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004)
"Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists."	2.40	Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997)
"Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks."	2.40	Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999)
"Arthralgias have been frequently cited as the primary reason for discontinuation of AI therapy."	1.38	Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. ( Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D, 2012)
"Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects."	1.36	Cognitive changes associated with endocrine therapy for breast cancer. ( Agrawal, K; Mortimer, JE; Onami, S; Pal, SK, 2010)
"The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk."	1.35	IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008)
"The current status of breast cancer prevention efforts was examined."	1.35	Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. ( Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA, 2008)
"The San Antonio Breast Cancer Symposium is now considered the most important international breast cancer meeting worldwide."	1.33	Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. ( Ponzone, R; Sismondi, P, 2005)
"Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen."	1.30	Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998)

Research

Studies (103)

Authors

Clinical Trials (17)

Trial Overview

Trial Outcomes

Clinical Benefit Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (8.74)	18.2507
2000's	60 (58.25)	29.6817
2010's	33 (32.04)	24.3611
2020's	1 (0.97)	2.80

Authors	Studies
Ghadjar, P	1
Aebersold, DM	1
Albrecht, C	1
Böhmer, D	1
Flentje, M	1
Ganswindt, U	1
Höcht, S	1
Hölscher, T	1
Müller, AC	1
Niehoff, P	1
Pinkawa, M	1
Sedlmayer, F	1
Zips, D	1
Wiegel, T	1
Carpenter, NA	1
Crook, EK	1
Zhang, J	1
Huang, Y	1
Wang, C	1
He, Y	1
Zheng, S	1
Wu, K	1
Gnant, M	1
Pfeiler, G	1
Stöger, H	1
Mlineritsch, B	1
Fitzal, F	1
Balic, M	1
Kwasny, W	1
Seifert, M	1
Stierer, M	1
Dubsky, P	1
Greil, R	1
Steger, G	1
Samonigg, H	1
Fesl, C	1
Jakesz, R	1
Kyvernitakis, I	1
Knöll, D	1
Struck, M	1
Hars, O	1
Bauer, T	1
Hadji, P	1
Mathew, A	1
Brufsky, A	1
Goss, PE	4
Hershman, DL	2
Cheung, AM	1
Ingle, JN	3
Khosla, S	1
Stearns, V	1
Chalchal, H	1
Rowland, K	1
Muss, HB	1
Linden, HM	1
Scher, J	1
Pritchard, KI	3
Elliott, CR	1
Badovinac-Crnjevic, T	1
St Louis, J	1
Chapman, JA	1
Shepherd, LE	1
Schmid, P	1
Pinder, SE	1
Wheatley, D	1
Macaskill, J	1
Zammit, C	1
Hu, J	1
Price, R	1
Bundred, N	1
Hadad, S	1
Shia, A	1
Sarker, SJ	1
Lim, L	1
Gazinska, P	1
Woodman, N	1
Korbie, D	1
Trau, M	1
Mainwaring, P	1
Gendreau, S	1
Lackner, MR	1
Derynck, M	1
Wilson, TR	1
Butler, H	1
Earl, G	1
Parker, P	1
Purushotham, A	1
Thompson, A	1
Lee, CI	1
Goodwin, A	1
Wilcken, N	1
Sanford, M	1
Plosker, GL	2
Nemitz, N	1
Kurmann, PT	1
Van Linthoudt, D	1
Nagykálnai, T	2
Kahán, Z	1
Cuzick, J	4
Sestak, I	2
Cella, D	1
Fallowfield, L	1
Duffy, SR	1
Distler, W	1
Howell, A	2
Baum, M	1
Collins, B	1
Mackenzie, J	1
Stewart, A	1
Bielajew, C	1
Verma, S	2
Azria, D	1
Jacot, W	1
Gligorov, J	1
Belkacémi, Y	1
Zaman, K	1
Romieu, G	1
Ozsahin, M	1
Smollich, M	1
Götte, M	1
Fischgräbe, J	1
Radke, I	1
Kiesel, L	1
Wülfing, P	1
Glück, S	1
Auboire, L	1
Landy, S	1
Perrot, JY	1
Maïza, D	1
Le Hello, C	1
Briot, K	1
Tubiana-Hulin, M	1
Bastit, L	1
Kloos, I	1
Roux, C	1
Cristofanilli, M	1
Valero, V	2
Mangalik, A	1
Royce, M	1
Rabinowitz, I	1
Arena, FP	1
Kroener, JF	1
Curcio, E	1
Watkins, C	1
Bacus, S	1
Cora, EM	1
Anderson, E	1
Magill, PJ	1
Fox, KR	1
Carlson, RW	1
Theriault, R	1
Schurman, CM	1
Rivera, E	1
Chung, CT	1
Phan, SC	1
Arun, B	1
Dice, K	1
Chiv, VY	1
Green, M	1
Agrawal, K	1
Onami, S	1
Mortimer, JE	1
Pal, SK	1
Lintermans, A	1
Van Calster, B	1
Van Hoydonck, M	1
Pans, S	1
Verhaeghe, J	1
Westhovens, R	1
Henry, NL	1
Wildiers, H	1
Paridaens, R	1
Dieudonné, AS	1
Leunen, K	1
Morales, L	1
Verschueren, K	1
Timmerman, D	1
De Smet, L	1
Vergote, I	1
Christiaens, MR	1
Neven, P	1
Hozumi, Y	2
Suemasu, K	2
Takei, H	3
Aihara, T	1
Takehara, M	2
Saito, T	1
Ohsumi, S	2
Masuda, N	2
Ohashi, Y	2
Miller, TW	1
Balko, JM	1
Ghazoui, Z	2
Dunbier, A	1
Anderson, H	2
Dowsett, M	9
González-Angulo, AM	1
Mills, GB	1
Miller, WR	6
Wu, H	1
Shyr, Y	1
Arteaga, CL	1
Recchia, F	1
Candeloro, G	1
Necozione, S	1
Desideri, G	1
Recchia, CO	1
Piazze, J	1
Rea, S	1
Dunbier, AK	1
Salter, J	3
Parker, JS	1
Perou, CM	1
Smith, IE	4
Stanway, SJ	1
Palmieri, C	1
Stanczyk, FZ	1
Folkerd, EJ	2
Ward, R	1
Coombes, RC	3
Reed, MJ	1
Purohit, A	1
Landherr, L	1
Mészáros, E	1
Llombart-Cussac, A	1
Ruiz, A	1
Antón, A	1
Barnadas, A	2
Antolín, S	1
Alés-Martínez, JE	1
Alvarez, I	1
Andrés, R	1
García Saenz, JA	1
Lao, J	1
Carrasco, E	1
Cámara, C	1
Casas, I	1
Martín, M	1
Shimozuma, K	1
Sagara, Y	1
Kinoshita, T	1
Iwata, H	1
Nakamura, S	1
Yanagita, Y	1
Nishimura, R	1
Iwase, H	1
Kamigaki, S	1
Noguchi, S	2
Menas, P	1
Merkel, D	1
Hui, W	1
Lawton, J	1
Harper, A	1
Carro, G	1
Tevaarwerk, A	1
Burkard, ME	1
Wisinski, KB	1
Shafer, MM	1
Davis, LA	1
Gogineni, J	1
Crone, E	1
Hansen, KE	1
Bergh, J	1
Jönsson, PE	1
Lidbrink, EK	1
Trudeau, M	2
Eiermann, W	1
Brattström, D	1
Lindemann, JP	1
Wiklund, F	1
Henriksson, R	1
Yu, KD	1
Zhou, Y	1
Liu, GY	1
Li, B	1
He, PQ	1
Zhang, HW	1
Lou, LH	1
Wang, XJ	1
Wang, S	1
Tang, JH	1
Liu, YH	1
Wang, X	1
Jiang, ZF	1
Ma, LW	1
Gu, L	1
Cao, MZ	1
Zhang, QY	1
Wang, SM	1
Su, FX	1
Zheng, H	1
Li, HY	1
Tang, LL	1
Sun, SR	1
Liu, JP	1
Shao, ZM	1
Shen, ZZ	1
Harvie, M	1
Forbes, JF	1
Dixon, JM	7
Renshaw, L	2
A'Hern, RP	1
Ligibel, JA	1
Winer, EP	2
Clarke Hillyer, G	1
Neugut, AI	1
Crew, KD	1
Kalinsky, K	1
Maurer, MA	1
Rotsides, DZ	1
Danaceau, J	1
Stuart, M	1
Sahmoud, T	1
Milla-Santos, A	1
Milla, L	1
Portella, J	1
Rallo, L	1
Pons, M	1
Rodes, E	1
Casanovas, J	1
Puig-Gali, M	1
Rose, C	1
Mouridsen, H	1
Gershanovich, M	1
Lønning, P	1
Pfister, C	1
Martoni, A	1
Zamagni, C	1
Fleming, GF	1
Nabholtz, JM	1
Buzdar, AU	7
Kawakami, M	1
Saji, S	1
Toi, M	1
McKeage, K	1
Curran, MP	1
Thürlimann, B	1
Hess, D	1
Köberle, D	1
Senn, I	1
Ballabeni, P	1
Pagani, O	1
Perey, L	1
Aebi, S	1
Rochlitz, C	1
Goldhirsch, A	1
Hillner, BE	1
Morandi, P	1
Rouzier, R	1
Altundag, K	1
Theriault, RL	1
Hortobagyi, G	1
de Cremoux, P	1
Diéras, V	1
Poupon, MF	1
Magdelénat, H	1
Sigal-Zafrani, B	1
Fourquet, A	1
Pierga, JY	1
Travis, K	1
Iaffaioli, RV	1
Formato, R	1
Tortoriello, A	1
Del Prete, S	1
Caraglia, M	1
Pappagallo, G	1
Pisano, A	1
Gebbia, V	1
Fanelli, F	1
Ianniello, G	1
Cigolari, S	1
Pizza, C	1
Marano, O	1
Pezzella, G	1
Pedicini, T	1
Febbraro, A	1
Incoronato, P	1
Manzione, L	1
Ferrari, E	1
Marzano, N	1
Quattrin, S	1
Pisconti, S	1
Nasti, G	1
Giotta, G	1
Colucci, G	1
Polychronis, A	1
Sinnett, HD	1
Hadjiminas, D	1
Singhal, H	1
Mansi, JL	1
Shivapatham, D	1
Shousha, S	1
Jiang, J	1
Peston, D	1
Barrett, N	1
Vigushin, D	1
Morrison, K	1
Beresford, E	1
Ali, S	1
Slade, MJ	1
Ponzone, R	1
Sismondi, P	1
Carlini, P	1
Bria, E	1
Giannarelli, D	1
Ferretti, G	1
Felici, A	1
Papaldo, P	1
Fabi, A	1
Nisticò, C	1
Di Cosimo, S	1
Ruggeri, EM	1
Milella, M	1
Mottolese, M	1
Terzoli, E	1
Cognetti, F	1
Dickler, M	1
Kijima, I	1
Itoh, T	1
Chen, S	1
Ebbs, SR	2
Skene, A	2
Griffith, C	1
Boeddinghaus, I	1
Detre, S	2
Hills, M	2
Ashley, S	1
Francis, S	1
Walsh, G	2
A'Hern, R	2
Cataliotti, L	1
Bines, J	1
Takatsuka, Y	1
Petrakova, K	1
Dube, P	1
de Oliveira, CT	1
Freedman, OC	1
Clemons, MJ	1
Gil, JM	1
Rubio-Terrés, C	1
Del Castillo, A	1
González, P	1
Canorea, F	1
Maciá Escalante, S	1
Pons Sanz, V	1
Rodríguez Lescure, A	1
Ballester Navarro, I	1
Carrato Mena, A	1
Manquez, ME	1
Brown, MM	1
Shields, CL	1
Shields, JA	1
Piskur, P	1
Sonc, M	1
Cufer, T	2
Borstnar, S	1
Mrhar, A	1
El-Saghir, NS	1
El-Hajj, II	1
Makarem, JA	1
Otrock, ZK	1
Mauri, D	1
Pavlidis, N	1
Polyzos, NP	1
Ioannidis, JP	1
Chien, AJ	1
Sahin, FI	1
Yilmaz, Z	1
Karakuş, S	1
Boğa, S	1
Akçali, Z	1
DemIrhan, B	1
Karnon, J	1
Delea, T	1
Barghout, V	1
O'Shaughnessy, J	1
Perez, EA	1
Come, SE	1
Johnston, SRD	1
Brodie, AM	1
Zujewski, JA	1
Eisen, A	1
Shelley, W	1
Messersmith, H	1
Carpenter, R	1
Aapro, M	1
Gil, M	1
Sánchez-Rovira, P	1
Llombart, A	1
Adrover, E	1
Estevez, LG	1
de la Haba, J	1
Calvo, L	1
Plourde, PV	1
Hortobagyi, GN	1
Roseman, BJ	1
Singletary, SE	1
Harvey, HA	2
Brodie, A	1
Lu, Q	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.[NCT00300508]	Phase 3	856 participants	Interventional	1996-01-31	Completed
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer[NCT00354302]	Phase 3	497 participants (Actual)	Interventional	2006-04-24	Completed
A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy[NCT00260975]		112 participants (Actual)	Observational	2001-06-30	Completed
The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.[NCT02303145]		187 participants (Actual)	Observational	2014-09-30	Completed
Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004]		40 participants (Actual)	Observational	2018-01-22	Completed
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women[NCT00186121]	Phase 2	35 participants (Actual)	Interventional	2000-10-31	Completed
Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer[NCT00128843]	Phase 2	103 participants (Actual)	Interventional	2001-08-31	Completed
Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients[NCT00605267]	Phase 3	197 participants (Actual)	Interventional	2007-10-31	Completed
Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial[NCT02532400]	Phase 3	21 participants (Actual)	Interventional	2016-03-31	Terminated (stopped due to Hard to enroll expected number of eligible patients.)
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?[NCT00766532]	Phase 4	12 participants (Actual)	Interventional	2009-01-31	Completed
A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer[NCT00769080]		524 participants (Actual)	Observational	2008-09-30	Completed
Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441]		204 participants (Anticipated)	Observational	2014-05-06	Recruiting
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665]		71 participants (Actual)	Interventional	2005-04-30	Completed
A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Br[NCT00232661]	Phase 3	452 participants (Actual)	Interventional	2000-08-31	Completed
Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916]	Early Phase 1	30 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.[NCT03784651]		120 participants (Anticipated)	Observational	2018-12-17	Recruiting
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477]	Phase 2	257 participants (Actual)	Interventional	2017-10-05	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The overall clinical benefit rate of goserelin followed by anastrozole was evaluated, as determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rate + Stable Disease (SD) rate.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months

Objective Response Rate (ORR)

Intervention	percentage of participants (Number)
Anastrozole + Goserelin	71.9

"ORR was determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rates.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 3 months

Overall Survival (OS)

Intervention	percentage of participants (Number)
Anastrozole + Goserelin	37.5

Overall survival (OS) was assessed as the median observed in the participants receiving goserelin followed by anastrozole. (NCT00186121)
Timeframe: up to 63 months

Serious Adverse Events

Intervention	months (Median)
Anastrozole + Goserelin	NA

The toxicity of the treatment regimen of goserelin followed by anastrozole is estimated by the rate of Serious Adverse Events (SAEs) that occurred during the course of the study. (NCT00186121)
Timeframe: 6 months

Time-to-Progression (TTP)

Intervention	Serious Adverse Events (SAEs) (Number)
Anastrozole + Goserelin	0

"Time-to-progression (TTP) was assessed as the median observed in the participant group.~Progression of disease was considered, per protocol, to be ≤ 25% increase in the area of any malignant lesion greater than 2 square cm, or ≤ 25% increase in the sum of the products of the longest perpendicular diameters of individual lesions in a given organ, when compared to baseline values or after therapeutic response." (NCT00186121)
Timeframe: up to 63 months

Estradiol Suppression

Intervention	months (Median)
Anastrozole + Goserelin	8.3

Plasma estradiol determinations were performed at baseline, 1 month, 3 months, and 6 months using the Coat-A-Count Estradiol competitive binding assay system, which has a calibrated range for estradiol of 20 to 3,600 pg/mL with an analytical sensitivity of 10 pg/mL. (NCT00186121)
Timeframe: 6 months

Response Rates

Intervention	pg/mL estradiol (Mean)
	Mean at Baseline	Mean at 1 month treatment	Mean at 3 months treatment	Mean at 6 months treatment
Anastrozole + Goserelin	74.7	20.8	18.7	14.8

"The numbers of participants with metastatic breast cancer experiencing Complete Response (CR); Partial Response (PR); or Stable Disease (SD) after treatment with goserelin followed by anastrozole are reported.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months

Anastrozole Plasma Concentrations (Cmin)

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Partial Response (PR)	Stable Disease (SD)
Anastrozole + Goserelin	1	11	11

Trough Plasma concentrations (Cmin) of Anastrozole - only Anastrozole arm was evaluated for Trough Plasma concentrations. (NCT00605267)
Timeframe: Assessed at week 12

Best Overall Response Rate (BORR) (Calliper)

Intervention	ng/mL (Geometric Mean)
Anastrozole 1 mg	29.7

"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from calliper measurement).~CR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by Calliper: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks

Best Overall Response Rate (BORR) (MRI/CT)

Intervention	Percentage of Participants (Number)
Anastrozole 1 mg	70.4
Tamoxifen 20 mg	50.5

"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period(based on the data from magnetic resonance imaging (MRI) or computed tomography (CT) measurement).~CR (or PR) criteria are met at either 12 weeks or 24 weeks. Per RECIST Criteria (V1.0) and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks

Best Overall Response Rate (BORR) (US)

Intervention	Percentage of Participants (Number)
Anastrozole 1 mg	64.3
Tamoxifen 20 mg	37.4

"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from ultra sound (US) measurement).~CR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by US: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks

Bone Mineral Density (BMD) Cervical Thighbone

Intervention	Participants (Number)
Anastrozole 1 mg	58.2
Tamoxifen 20 mg	42.4

Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at cervical thighbone. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Bone Mineral Density (BMD) Lumbar Spine

Intervention	PercentageBMD=Patient'sBMD/standard BMD) (Mean)
Anastrozole 1 mg	-2.5
Tamoxifen 20 mg	-0.5

Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at lumbar spine. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Bone Turnover Marker (BAP) CLEIA Method

Intervention	PercentageBMD=Patient's BMD/standard BMD (Mean)
Anastrozole 1 mg	-5.8
Tamoxifen 20 mg	-2.9

Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by CLEIA method (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Bone Turnover Marker (BAP) EIA Method

Intervention	ug/L (Mean)
Anastrozole 1 mg	3.96
Tamoxifen 20 mg	-0.75

Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by EIA method (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Bone Turnover Marker (NTX)

Intervention	U/L (Mean)
Anastrozole 1 mg	7.1941
Tamoxifen 20 mg	0.7333

Change from baseline in serum crosslinked N-Telopeptide of type I collagen (NTX) at 24 weeks (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Endocrine Subscale (ES)

Intervention	nmolBCE(Bone Collagen Equivalent) /L (Mean)
Anastrozole 1 mg	9.17
Tamoxifen 20 mg	2.59

"Change from baseline in Endocrine Symptom Subscale (ES)) in the ITT population at 24 weeks. ES score = the sum of the responses to all the questions on ES, low scores reflect poor quality of life and high scores reflects better quality of life.~Score range: 0-72" (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Functional Assessment of Cancer Therapy-Breast (FACT-B)

Intervention	ES score (Mean)
Anastrozole 1 mg	-8.85
Tamoxifen 20 mg	-6.27

"Change from baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B)in the ITT population at 24 weeks. Trial Outcome Index (TOI) = the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and Breast Cancer Scale (BCS) subscales of FACT-B.~FACT-B includes 36 questions; 7 in PWB (Physical Well-Being); 7 inSWB (Social / Family Well-Being); 6 in EWB (Emotional Well-Being); 7 in FWB (Functional Well-Being); 9 in BCS (Breast Cancer Subscale).~Total score of subscores or TOI is calculated from each score of question. Higher score means better and lower score means worthier.~Score range; 0-28 in PWB; 0-28 in SWB; 0-24 in EWB; 0-28 in FWB; 0-36 in BCS; 0-92 in TOI." (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Histopathological Response Rate (HRR)

Intervention	Trial Outcome Index (TOI) (Prorated) (Mean)
Anastrozole 1 mg	-4.42
Tamoxifen 20 mg	-2.65

Number of patients in the ITT population defined as histopathological responders over the total number of patients x 100. An histopathological responder = a patient classified as Grade 1b, 2 or 3 for the histopathological response (Grade 0 = no response, 1a = mild response, 1b = moderate response, 2 = marked response or 3 = complete response) (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Serum Oestradiol (E2) Concentrations

Intervention	Percentage of Participants (Number)
Anastrozole 1 mg	41.8
Tamoxifen 20 mg	27.3

Ratio of serum Oestradiol (E2) concentration (pg/mL) in the ITT population from baseline at 24 weeks. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Serum Oestrone (E1) Concentrations

Intervention	Ratio (Mean)
Anastrozole 1 mg	0.041
Tamoxifen 20 mg	0.082

Ratio of serum Oestrone (E1) concentration (pg/mL) in the ITT population from baseline at 24 weeks. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Human Epidermal Growth Factor Receptor 2 (HER2) Status

Intervention	Ratio (Mean)
Anastrozole 1 mg	0.028
Tamoxifen 20 mg	0.341

HER2 status in the ITT population is categorized as Positive or Negative (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Oestrogen Receptor (ER) Status

Intervention	Participants (Number)
	Baseline Positive & 24 weeks Negative	Baseline Positive & 24 weeks Positive	Baseline Negative & 24 weeks Negative	Baseline Negative & 24 weeks Positive
Anastrozole 1 mg	0	0	92	2
Tamoxifen 20 mg	0	0	88	2

ER status in the ITT population is categorized as Positive or Negative (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Progesterone Receptor (PgR) Status

Intervention	Participants (Number)
	Baseline Positive & 24 weeks Negative	Baseline Positive & 24 weeks Positive	Baseline Negative & 24 weeks Negative	Baseline Negative & 24 weeks Positive
Anastrozole 1 mg	2	92	0	0
Tamoxifen 20 mg	1	89	0	0

PgR status in the ITT population is categorized as Positive or Negative. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment

Change in Intestinal Calcium Absorption Related to Aromatase Inhibitor Therapy

Intervention	Participants (Number)
	Baseline Positive & 24 weeks Negative	Baseline Positive & 24 weeks Positive	Baseline Negative & 24 weeks Negative	Baseline Negative & 24 weeks Positive
Anastrozole 1 mg	60	29	4	1
Tamoxifen 20 mg	19	59	9	3

intestinal calcium absorption (NCT00766532)
Timeframe: baseline and 6 weeks later

Article	Year
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. British journal of cancer, 2013, Aug-06, Volume: 109, Issue:3 Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind	2013
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. The Lancet. Oncology, 2014, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat	2014
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 06-10, Volume: 34, Issue:17 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu	2016
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast cancer research and treatment, 2010, Volume: 120, Issue:1 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans	2010
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast	2010
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea? Current oncology reports, 2010, Volume: 12, Issue:1 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di	2010
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-01, Volume: 28, Issue:25 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem	2010
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot	2011
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. Cancer, 2012, Jan-01, Volume: 118, Issue:1 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh	2012
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- Breast cancer research and treatment, 2012, Volume: 133, Issue:1 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;	2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo	2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo	2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo	2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo	2012
Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast cancer research and treatment, 2012, Volume: 134, Issue:1 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Calcium;	2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast	2012
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast cancer research and treatment, 2012, Volume: 134, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo	2012
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. Journal of oncology practice, 2012, Volume: 8, Issue:5 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Medication Adh	2012
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. British journal of cancer, 2002, Oct-21, Volume: 87, Issue:9 Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors	2002
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. American journal of clinical oncology, 2003, Volume: 26, Issue:3 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neo	2003
Advanced breast cancer updates on anastrozole versus tamoxifen. The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administra	2003
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Breast cancer research and treatment, 2004, Volume: 85, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cros	2004
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer, 2004, Oct-01, Volume: 101, Issue:7 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms	2004
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. British journal of cancer, 2005, May-09, Volume: 92, Issue:9 Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ant	2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. The Lancet. Oncology, 2005, Volume: 6, Issue:6 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind M	2005
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status? Nature clinical practice. Oncology, 2005, Volume: 2, Issue:10 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Respon	2005
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 2 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto	2006
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer, 2006, May-15, Volume: 106, Issue:10 Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Re	2006
A decade of letrozole: FACE. Breast cancer research and treatment, 2007, Volume: 105 Suppl 1 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast	2007

anastrozole and Hormone-Dependent Neoplasms